CLYM (Climb Bio) Accounts Payable: $0.86 Mil (As of Mar. 2026)


CLYM Climb Bio Inc CLYM
22 GF Score
Price $13.63
! 3 Warning Signs
View Full Analysis

What is Climb Bio Accounts Payable?

Climb Bio CLYM +2.75% 22 Accounts Payable is $0.86 Mil as of Mar. 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Climb Bio's Accounts Payable for the quarter that ended in Mar. 2026 was $0.86 Mil.

Climb Bio's quarterly Accounts Payable increased from Sep. 2025 ($0.48 Mil) to Dec. 2025 ($2.27 Mil) but then declined from Dec. 2025 ($2.27 Mil) to Mar. 2026 ($0.86 Mil).

Climb Bio's annual Accounts Payable increased from Dec. 2023 ($0.07 Mil) to Dec. 2024 ($0.71 Mil) and increased from Dec. 2024 ($0.71 Mil) to Dec. 2025 ($2.27 Mil).

Climb Bio Accounts Payable Historical Data

* Premium members only.

The historical data trend for Climb Bio's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Climb Bio Accounts Payable Chart

Climb Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 1.40 0.75 0.07 0.71 2.27

Climb Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.95 0.48 2.27 0.86
CLYM
22GF Score
Climb Bio Inc CLYM
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Climb Bio Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.86 Mil mean?
Climb Bio (CLYM) has a Accounts Payable of $0.86 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Climb Bio and its competitors.
Is Climb Bio's Accounts Payable too high?
Climb Bio's current Accounts Payable is $0.86 Mil. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's Accounts Payable compare to XOMA and CTMX?
Climb Bio's Accounts Payable of $0.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Climb Bio and its competitors. Climb Bio's current Accounts Payable is $0.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current Accounts Payable of $0.86 Mil. The current Accounts Payable is $0.86 Mil. Climb Bio's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Climb Bio (CLYM), the current Accounts Payable is $0.86 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.63
Price